Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 9/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23924365 | 1.00 | RORC (0.51) | RORCROCK2ROCK1P2RX7CCR2 | |
| SCHEMBL29900609 | 1.00 | RORC (0.51) | RORCROCK2ROCK1P2RX7CCR2 | |
| SCHEMBL23951506 | 1.00 | RORC (0.51) | RORCROCK2ROCK1P2RX7CCR2 | |
| SCHEMBL23924265 | 0.83 | ALDH1A1 (0.41) | ROCK2P2RX7 | |
| SCHEMBL23924266 | 0.83 | ALDH1A1 (0.41) | ROCK2P2RX7 | |
| SCHEMBL20139670 | 0.81 | RORC (0.71) | RORCDRD4 | |
| SCHEMBL20141807 | 0.81 | RORC (0.71) | RORCDRD4 | |
| SCHEMBL28932959 | 0.77 | RORC (0.46) | RORCP2RX7MAPT | |
| SCHEMBL23951504 | 0.77 | RORC (0.46) | RORCP2RX7MAPT | |
| SCHEMBL23951260 | 0.76 | BACE1 (0.44) | ROCK2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | RORC 46/4885ROCK2 2207/4885ROCK1 3857/4885 |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | RORC 46/4885ROCK2 2207/4885ROCK1 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.